To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Zelsuvmi

Berdazimer
Antiviral
Topical Gel

Zelsuvmi is a topical gel applied to molluscum contagiosum skin lesions in patients aged one year and older. The gel releases nitric oxide to clear lesions and is the only at-home prescription treatment for this viral infection.

Approval Date
05-Jan-24
NCE-1 Date
05-Jan-28
NCE Date
05-Jan-29
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
6
2027
13
2028
17
2029
24
2030
29
2031
35
2032
40
Molecule profile

Details & specifications

Molecule
Berdazimer
Innovator
LNHC INC
Dosage Form
Topical Gel
Strength
EQ 10.3% base
Therapeutic Category
Antiviral
Usage
To treat molluscum contagiosum
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

When will Zelsuvmi go generic?
What is the NCE-1 date for Zelsuvmi?
What are Zelsuvmi’s sales?
When was Zelsuvmi approved?
The 5-year NCE exclusivity for Zelsuvmi (berdazimer) runs until 5 January 2029, so generic entry is not expected before then. Actual launch timing also depends on any patents, other exclusivities, Paragraph IV litigation and FDA review.
The NCE-1 date for Zelsuvmi (berdazimer) is 5 January 2028, four years after approval. From that date, if patents are listed for it in the FDA Orange Book, generic companies can submit an ANDA with a Paragraph IV certification challenging them. The first filer may qualify for 180-day generic exclusivity.
Sales of Zelsuvmi (berdazimer) are projected to grow from about $6M in 2026 to about $40M by 2032. The innovator is LNHC Inc.
The FDA approved Zelsuvmi (berdazimer) on 5 January 2024. It is used to treat molluscum contagiosum. The innovator is LNHC Inc and it is available as a topical gel.

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?